Drawing for SOCIOMICS

USPTO serial 97356365

SOCIOMICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MAHONEY, KATHERINE AILEEN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SOCIOMICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roger H. Bora

Roger H. Bora THOMPSON HINE LLPAUSTIN LANDING, DISCOVERY PLACE BLDG.10050 INNOVATION DRIVE, SUITE 400DAYTON, OH 45342

Goods and services

ClassDescriptionStatusFirst use
042Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, and the data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing, analysis, and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of analyzing how an individual's cultural and environmental factors affect their response to drugs, and for the purposes of improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs switching; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors, together with genetic variants, epigenetic factors and multiomics to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of supporting drug clinical trials and research into the field of new drug development and drug repurposing; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation to determine a patient's medication and drug response associated with cultural and environmental factors, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's periodic changes in response to medical treatment, pharmacological adverse reactions, drug-drug interactions, drug dosing changes, and new or recurring comorbiditiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 22, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 22, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 7, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 7, 2025EX5GSOU EXTENSION 5 GRANTED—
Nov 5, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 4, 2025EXT5SOU EXTENSION 5 FILED—
Apr 25, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 24, 2025EX4GSOU EXTENSION 4 GRANTED—
Apr 24, 2025EXT4SOU EXTENSION 4 FILED—
Apr 24, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 2, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 2, 2025EX3GSOU EXTENSION 3 GRANTED—
Jan 2, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 14, 2024EXT3SOU EXTENSION 3 FILED—
Nov 14, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 18, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 18, 2024EX2GSOU EXTENSION 2 GRANTED—
Apr 18, 2024EXT2SOU EXTENSION 2 FILED—
Apr 18, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 1, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 30, 2023EX1GSOU EXTENSION 1 GRANTED—
Oct 30, 2023EXT1SOU EXTENSION 1 FILED—
Oct 30, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 16, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 21, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 21, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 1, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 10, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 9, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 9, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 9, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 11, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 11, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 15, 2022DOCKASSIGNED TO EXAMINER—
Apr 15, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 14, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance